

【SR-10 メタアナリシス】

CQ		HER2陰性転移・再発乳癌に対する一次・二次治療化学療法として、ペバシズマブを併用することは推奨されるか？																																																						
P	HER2陰性転移・再発乳癌（女性）	I	ペバシズマブ+化学療法																																																					
C	化学療法	O	OS																																																					
研究デザイン	RCT	文献数	8																																																					
コード	Miller2005(AVF2119g), Miller2007(E2100), Miles2010(AVADO), Robert2011(RIBBON-1), Brufsky2011(RIBBON-2), Minckwitz2014(TANIA), Miles D2017(MERiDian)																																																							
モデル	Random Effect	方法	Inverse Variance method (RevMan5.3)																																																					
効果指標	Hazard Ratio	統合値	0.94 (0.86-1.01 ) P= 0.11																																																					
フォレスト プロット	<table border="1"> <thead> <tr> <th>Study or Subgroup</th> <th>log[Hazard Ratio]</th> <th>SE</th> <th>Weight</th> <th>Hazard Ratio IV, Random, 95% CI</th> <th>Hazard Ratio IV, Random, 95% CI</th> </tr> </thead> <tbody> <tr> <td>Brufsky 2011 (RIBBON-2)</td> <td>-0.1054</td> <td>0.121</td> <td>11.7%</td> <td>0.90 [0.71, 1.14]</td> <td rowspan="8"> </td> </tr> <tr> <td>Miles 2010 (AVADO)</td> <td>0.0392</td> <td>0.1029</td> <td>16.2%</td> <td>1.04 [0.85, 1.27]</td> </tr> <tr> <td>Miles D 2017 (MERIDIAN)</td> <td>-0.2107</td> <td>0.1447</td> <td>8.2%</td> <td>0.81 [0.61, 1.08]</td> </tr> <tr> <td>Miller 2005 (AVF2119g)</td> <td>0.0677</td> <td>0.1174</td> <td>12.4%</td> <td>1.07 [0.85, 1.35]</td> </tr> <tr> <td>Miller 2007 (E2100)</td> <td>-0.1508</td> <td>0.0836</td> <td>24.5%</td> <td>0.86 [0.73, 1.01]</td> </tr> <tr> <td>Minckwitz 2014 (TANIA)</td> <td>-0.0408</td> <td>0.1192</td> <td>12.0%</td> <td>0.96 [0.76, 1.21]</td> </tr> <tr> <td>Robert 2011 (RIBBON-1 Cape cohort)</td> <td>-0.1625</td> <td>0.1528</td> <td>7.3%</td> <td>0.85 [0.63, 1.15]</td> </tr> <tr> <td>Robert 2011 (RIBBON-1 T+Antra cohort)</td> <td>0.0296</td> <td>0.1484</td> <td>7.8%</td> <td>1.03 [0.77, 1.38]</td> </tr> <tr> <td><b>Total (95% CI)</b></td> <td></td> <td></td> <td><b>100.0%</b></td> <td><b>0.94 [0.86, 1.01]</b></td> </tr> </tbody> </table> <p>Heterogeneity: Tau<sup>2</sup> = 0.00; Chi<sup>2</sup> = 5.34, df = 7 (P = 0.62); I<sup>2</sup> = 0% Test for overall effect Z = 1.60 (P = 0.11)</p>				Study or Subgroup	log[Hazard Ratio]	SE	Weight	Hazard Ratio IV, Random, 95% CI	Hazard Ratio IV, Random, 95% CI	Brufsky 2011 (RIBBON-2)	-0.1054	0.121	11.7%	0.90 [0.71, 1.14]		Miles 2010 (AVADO)	0.0392	0.1029	16.2%	1.04 [0.85, 1.27]	Miles D 2017 (MERIDIAN)	-0.2107	0.1447	8.2%	0.81 [0.61, 1.08]	Miller 2005 (AVF2119g)	0.0677	0.1174	12.4%	1.07 [0.85, 1.35]	Miller 2007 (E2100)	-0.1508	0.0836	24.5%	0.86 [0.73, 1.01]	Minckwitz 2014 (TANIA)	-0.0408	0.1192	12.0%	0.96 [0.76, 1.21]	Robert 2011 (RIBBON-1 Cape cohort)	-0.1625	0.1528	7.3%	0.85 [0.63, 1.15]	Robert 2011 (RIBBON-1 T+Antra cohort)	0.0296	0.1484	7.8%	1.03 [0.77, 1.38]	<b>Total (95% CI)</b>			<b>100.0%</b>	<b>0.94 [0.86, 1.01]</b>
	Study or Subgroup	log[Hazard Ratio]	SE	Weight	Hazard Ratio IV, Random, 95% CI	Hazard Ratio IV, Random, 95% CI																																																		
Brufsky 2011 (RIBBON-2)	-0.1054	0.121	11.7%	0.90 [0.71, 1.14]																																																				
Miles 2010 (AVADO)	0.0392	0.1029	16.2%	1.04 [0.85, 1.27]																																																				
Miles D 2017 (MERIDIAN)	-0.2107	0.1447	8.2%	0.81 [0.61, 1.08]																																																				
Miller 2005 (AVF2119g)	0.0677	0.1174	12.4%	1.07 [0.85, 1.35]																																																				
Miller 2007 (E2100)	-0.1508	0.0836	24.5%	0.86 [0.73, 1.01]																																																				
Minckwitz 2014 (TANIA)	-0.0408	0.1192	12.0%	0.96 [0.76, 1.21]																																																				
Robert 2011 (RIBBON-1 Cape cohort)	-0.1625	0.1528	7.3%	0.85 [0.63, 1.15]																																																				
Robert 2011 (RIBBON-1 T+Antra cohort)	0.0296	0.1484	7.8%	1.03 [0.77, 1.38]																																																				
<b>Total (95% CI)</b>			<b>100.0%</b>	<b>0.94 [0.86, 1.01]</b>																																																				
	コメント：有意水準に達しない																																																							
ファンネル プロット																																																								
	コメント：出版バイアスは大きくはない																																																							
その他の解析	施行せず		コメント：																																																					
メタリグ レッション																																																								
感度分析																																																								

【SR-10 メタアナリシス】

CQ		HER2陰性転移・再発乳癌に対する一次・二次治療化学療法として、ベバシズマブを併用することは推奨されるか？																																																																	
P	HER2陰性転移・再発乳癌（女性）	I	ベバシズマブ+化学療法																																																																
C	化学療法	O	PFS																																																																
研究デザイン	RCT	文献数	9																																																																
コード	Miller2005(AVF2119g), Miller2007(E2100), Miles2010(AVADO), Martin2011, Robert2011(RIBBON-1), Brufsky2011(RIBBON-2), Minckwitz2014(TANIA), Miles D2017(MERiDian)																																																																		
モデル	Random Effect	方法	Inverse Variance method (RevMan5.3)																																																																
効果指標	Hazard Ratio	統合値	0.73 (0.65-0.81 ) P< 0.00001																																																																
フォレスト プロット	<table border="1"> <thead> <tr> <th>Study or Subgroup</th> <th>log[Hazard Ratio]</th> <th>SE</th> <th>Weight</th> <th>Hazard Ratio</th> <th>Hazard Ratio</th> </tr> <tr> <th></th> <th></th> <th></th> <th></th> <th>IV, Random, 95% CI</th> <th>IV, Random, 95% CI</th> </tr> </thead> <tbody> <tr> <td>Brufsky 2011 (RIBBON-2)</td> <td>-0.2485</td> <td>0.1009</td> <td>12.5%</td> <td>0.78 [0.64, 0.95]</td> <td rowspan="10"> </td> </tr> <tr> <td>Martin 2011</td> <td>-0.2357</td> <td>0.2037</td> <td>5.5%</td> <td>0.79 [0.53, 1.18]</td> </tr> <tr> <td>Miles 2010 (AVADO)</td> <td>-0.3147</td> <td>0.0752</td> <td>15.2%</td> <td>0.73 [0.63, 0.85]</td> </tr> <tr> <td>Miles D 2017 (MERIDIAN)</td> <td>-0.3857</td> <td>0.1468</td> <td>8.6%</td> <td>0.68 [0.51, 0.91]</td> </tr> <tr> <td>Miller 2005 (AVF2119g)</td> <td>-0.0202</td> <td>0.123</td> <td>10.4%</td> <td>0.98 [0.77, 1.25]</td> </tr> <tr> <td>Miller 2007 (E2100)</td> <td>-0.5798</td> <td>0.0786</td> <td>14.8%</td> <td>0.56 [0.46, 0.65]</td> </tr> <tr> <td>Minckwitz 2014 (TANIA)</td> <td>-0.2877</td> <td>0.1054</td> <td>12.0%</td> <td>0.75 [0.61, 0.92]</td> </tr> <tr> <td>Robert 2011 (RIBBON-1 Cape cohort)</td> <td>-0.3857</td> <td>0.1176</td> <td>10.9%</td> <td>0.69 [0.54, 0.86]</td> </tr> <tr> <td>Robert 2011 (RIBBON-1 T+Antra cohort)</td> <td>-0.2614</td> <td>0.1273</td> <td>10.0%</td> <td>0.77 [0.60, 0.99]</td> </tr> <tr> <td><b>Total (95% CI)</b></td> <td></td> <td></td> <td><b>100.0%</b></td> <td><b>0.73 [0.65, 0.81]</b></td> </tr> </tbody> </table> <p>Heterogeneity: Tau<sup>2</sup> = 0.01; Chi<sup>2</sup> = 18.13, df = 8 (P = 0.02), I<sup>2</sup> = 56% Test for overall effect: Z = 5.66 (P &lt; 0.00001)</p>				Study or Subgroup	log[Hazard Ratio]	SE	Weight	Hazard Ratio	Hazard Ratio					IV, Random, 95% CI	IV, Random, 95% CI	Brufsky 2011 (RIBBON-2)	-0.2485	0.1009	12.5%	0.78 [0.64, 0.95]		Martin 2011	-0.2357	0.2037	5.5%	0.79 [0.53, 1.18]	Miles 2010 (AVADO)	-0.3147	0.0752	15.2%	0.73 [0.63, 0.85]	Miles D 2017 (MERIDIAN)	-0.3857	0.1468	8.6%	0.68 [0.51, 0.91]	Miller 2005 (AVF2119g)	-0.0202	0.123	10.4%	0.98 [0.77, 1.25]	Miller 2007 (E2100)	-0.5798	0.0786	14.8%	0.56 [0.46, 0.65]	Minckwitz 2014 (TANIA)	-0.2877	0.1054	12.0%	0.75 [0.61, 0.92]	Robert 2011 (RIBBON-1 Cape cohort)	-0.3857	0.1176	10.9%	0.69 [0.54, 0.86]	Robert 2011 (RIBBON-1 T+Antra cohort)	-0.2614	0.1273	10.0%	0.77 [0.60, 0.99]	<b>Total (95% CI)</b>			<b>100.0%</b>	<b>0.73 [0.65, 0.81]</b>
Study or Subgroup	log[Hazard Ratio]	SE	Weight	Hazard Ratio	Hazard Ratio																																																														
				IV, Random, 95% CI	IV, Random, 95% CI																																																														
Brufsky 2011 (RIBBON-2)	-0.2485	0.1009	12.5%	0.78 [0.64, 0.95]																																																															
Martin 2011	-0.2357	0.2037	5.5%	0.79 [0.53, 1.18]																																																															
Miles 2010 (AVADO)	-0.3147	0.0752	15.2%	0.73 [0.63, 0.85]																																																															
Miles D 2017 (MERIDIAN)	-0.3857	0.1468	8.6%	0.68 [0.51, 0.91]																																																															
Miller 2005 (AVF2119g)	-0.0202	0.123	10.4%	0.98 [0.77, 1.25]																																																															
Miller 2007 (E2100)	-0.5798	0.0786	14.8%	0.56 [0.46, 0.65]																																																															
Minckwitz 2014 (TANIA)	-0.2877	0.1054	12.0%	0.75 [0.61, 0.92]																																																															
Robert 2011 (RIBBON-1 Cape cohort)	-0.3857	0.1176	10.9%	0.69 [0.54, 0.86]																																																															
Robert 2011 (RIBBON-1 T+Antra cohort)	-0.2614	0.1273	10.0%	0.77 [0.60, 0.99]																																																															
<b>Total (95% CI)</b>			<b>100.0%</b>	<b>0.73 [0.65, 0.81]</b>																																																															
	コメント：Beva群で有意にPFS良好。異質性ありの判定であるが、全体の傾向は同じでありこのSRをそのまま採用。																																																																		
ファンネル プロット																																																																			
	コメント：出版バイアスは大きくはない																																																																		
その他の解析	施行せず		コメント：																																																																
メタリグ レッション																																																																			
感度分析																																																																			

【SR-10 メタアナリシス】

CQ		HER2陰性転移・再発乳癌に対する一次・二次治療化学療法として、ベバシズマブを併用することは推奨されるか？																																																																																																					
P	HER2陰性転移・再発乳癌（女性）	I	ベバシズマブ+化学療法																																																																																																				
C	化学療法	O	ORR																																																																																																				
研究デザイン	RCT	文献数	9																																																																																																				
コード	Miller2005(AVF2119g), Miller2007(E2100), Miles2010(AVADO), Martin2011, Robert2011(RIBBON-1), Brufsky2011(RIBBON-2), Minckwitz2014(TANIA), Miles D2017(MERiDian)																																																																																																						
モデル	Random Effect	方法	Mantel-Haenszel method																																																																																																				
効果指標	Risk Ratio	統合値	1.49 (1.30-1.70 ) P< 0.00001																																																																																																				
フォレスト プロット	<table border="1"> <thead> <tr> <th>Study or Subgroup</th> <th>Beva+CTx Events</th> <th>Total</th> <th>CTx Events</th> <th>Total</th> <th>Weight</th> <th>Risk Ratio M-H, Random, 95% CI</th> </tr> </thead> <tbody> <tr> <td>Brufsky 2011 (RIBBON-2)</td> <td>143</td> <td>362</td> <td>53</td> <td>179</td> <td>12.0%</td> <td>1.33 [1.03, 1.73]</td> </tr> <tr> <td>Martin 2011</td> <td>50</td> <td>97</td> <td>39</td> <td>94</td> <td>10.1%</td> <td>1.24 [0.91, 1.69]</td> </tr> <tr> <td>Miles 2010 (AVADO)</td> <td>243</td> <td>407</td> <td>96</td> <td>207</td> <td>16.3%</td> <td>1.29 [1.09, 1.52]</td> </tr> <tr> <td>Miles D 2017 (MERIDIAN)</td> <td>129</td> <td>239</td> <td>30</td> <td>242</td> <td>14.0%</td> <td>1.63 [1.32, 2.02]</td> </tr> <tr> <td>Miller 2005 (AVF2119g)</td> <td>46</td> <td>232</td> <td>21</td> <td>230</td> <td>5.6%</td> <td>2.17 [1.34, 3.52]</td> </tr> <tr> <td>Miller 2007 (E2100)</td> <td>112</td> <td>229</td> <td>54</td> <td>243</td> <td>11.5%</td> <td>2.20 [1.68, 2.89]</td> </tr> <tr> <td>Minckwitz 2014 (TANIA)</td> <td>38</td> <td>182</td> <td>31</td> <td>185</td> <td>6.7%</td> <td>1.25 [0.81, 1.91]</td> </tr> <tr> <td>Robert 2011 (RIBBON-1 Cape cohort)</td> <td>115</td> <td>325</td> <td>38</td> <td>161</td> <td>9.9%</td> <td>1.50 [1.09, 2.05]</td> </tr> <tr> <td>Robert 2011 (RIBBON-1 T+Antra cohort)</td> <td>177</td> <td>345</td> <td>67</td> <td>177</td> <td>14.0%</td> <td>1.36 [1.09, 1.68]</td> </tr> <tr> <td><b>Total (95% CI)</b></td> <td></td> <td><b>2418</b></td> <td></td> <td><b>1718</b></td> <td><b>100.0%</b></td> <td><b>1.49 [1.30, 1.70]</b></td> </tr> <tr> <td>Total events</td> <td>1053</td> <td></td> <td>479</td> <td></td> <td></td> <td></td> </tr> <tr> <td colspan="7">Heterogeneity: Tau<sup>2</sup> = 0.02; Chi<sup>2</sup> = 17.40, df = 8 (P = 0.03); I<sup>2</sup> = 54%</td> </tr> <tr> <td colspan="7">Test for overall effect: Z = 5.87 (P &lt; 0.00001)</td> </tr> </tbody> </table>					Study or Subgroup	Beva+CTx Events	Total	CTx Events	Total	Weight	Risk Ratio M-H, Random, 95% CI	Brufsky 2011 (RIBBON-2)	143	362	53	179	12.0%	1.33 [1.03, 1.73]	Martin 2011	50	97	39	94	10.1%	1.24 [0.91, 1.69]	Miles 2010 (AVADO)	243	407	96	207	16.3%	1.29 [1.09, 1.52]	Miles D 2017 (MERIDIAN)	129	239	30	242	14.0%	1.63 [1.32, 2.02]	Miller 2005 (AVF2119g)	46	232	21	230	5.6%	2.17 [1.34, 3.52]	Miller 2007 (E2100)	112	229	54	243	11.5%	2.20 [1.68, 2.89]	Minckwitz 2014 (TANIA)	38	182	31	185	6.7%	1.25 [0.81, 1.91]	Robert 2011 (RIBBON-1 Cape cohort)	115	325	38	161	9.9%	1.50 [1.09, 2.05]	Robert 2011 (RIBBON-1 T+Antra cohort)	177	345	67	177	14.0%	1.36 [1.09, 1.68]	<b>Total (95% CI)</b>		<b>2418</b>		<b>1718</b>	<b>100.0%</b>	<b>1.49 [1.30, 1.70]</b>	Total events	1053		479				Heterogeneity: Tau <sup>2</sup> = 0.02; Chi <sup>2</sup> = 17.40, df = 8 (P = 0.03); I <sup>2</sup> = 54%							Test for overall effect: Z = 5.87 (P < 0.00001)						
Study or Subgroup	Beva+CTx Events	Total	CTx Events	Total	Weight	Risk Ratio M-H, Random, 95% CI																																																																																																	
Brufsky 2011 (RIBBON-2)	143	362	53	179	12.0%	1.33 [1.03, 1.73]																																																																																																	
Martin 2011	50	97	39	94	10.1%	1.24 [0.91, 1.69]																																																																																																	
Miles 2010 (AVADO)	243	407	96	207	16.3%	1.29 [1.09, 1.52]																																																																																																	
Miles D 2017 (MERIDIAN)	129	239	30	242	14.0%	1.63 [1.32, 2.02]																																																																																																	
Miller 2005 (AVF2119g)	46	232	21	230	5.6%	2.17 [1.34, 3.52]																																																																																																	
Miller 2007 (E2100)	112	229	54	243	11.5%	2.20 [1.68, 2.89]																																																																																																	
Minckwitz 2014 (TANIA)	38	182	31	185	6.7%	1.25 [0.81, 1.91]																																																																																																	
Robert 2011 (RIBBON-1 Cape cohort)	115	325	38	161	9.9%	1.50 [1.09, 2.05]																																																																																																	
Robert 2011 (RIBBON-1 T+Antra cohort)	177	345	67	177	14.0%	1.36 [1.09, 1.68]																																																																																																	
<b>Total (95% CI)</b>		<b>2418</b>		<b>1718</b>	<b>100.0%</b>	<b>1.49 [1.30, 1.70]</b>																																																																																																	
Total events	1053		479																																																																																																				
Heterogeneity: Tau <sup>2</sup> = 0.02; Chi <sup>2</sup> = 17.40, df = 8 (P = 0.03); I <sup>2</sup> = 54%																																																																																																							
Test for overall effect: Z = 5.87 (P < 0.00001)																																																																																																							
	コメント：Beva群で有意にORR良好。異質性ありの判定であるが、全体の傾向は同じでありこのSRをそのまま採用。																																																																																																						
ファンネル プロット																																																																																																							
	コメント：出版バイアスは大きくはない																																																																																																						
その他の解析	施行せず			コメント：																																																																																																			
メタリグ レッション																																																																																																							
感度分析																																																																																																							

【SR-10 メタアナリシス】

CQ		HER2陰性転移・再発乳癌に対する一次・二次治療化学療法として、ベバシズマブを併用することは推奨されるか？																																																																																																					
P	HER2陰性転移・再発乳癌（女性）	I	ベバシズマブ+化学療法																																																																																																				
C	化学療法	O	Toxicity (Therapy discontinuation)																																																																																																				
研究デザイン	RCT	文献数	8																																																																																																				
コード	Miller2005(AVF2119g), Miller2007(E2100), Miles2010(AVADO), Martin2011, Robert2011(RIBBON-1), Brufsky2011(RIBBON-2), Minckwitz2014(TANIA), Miles D2017(MERiDian)																																																																																																						
モデル	Random Effect	方法	Mantel-Haenszel method																																																																																																				
効果指標	Risk Ratio	統合値	1.42 (1.10-1.82 ) P= 0.006																																																																																																				
フォレスト プロット	<table border="1"> <thead> <tr> <th>Study or Subgroup</th> <th>Beva+CTx Events</th> <th>Total</th> <th>CTx Events</th> <th>Total</th> <th>Weight</th> <th>Risk Ratio M-H, Random, 95% CI</th> </tr> </thead> <tbody> <tr> <td>Brufsky 2011 (RIBBON-2)</td> <td>61</td> <td>458</td> <td>16</td> <td>221</td> <td>10.0%</td> <td>1.84 [1.09, 3.11]</td> </tr> <tr> <td>Martin 2011</td> <td>22</td> <td>96</td> <td>12</td> <td>89</td> <td>8.2%</td> <td>1.70 [0.89, 3.23]</td> </tr> <tr> <td>Miles 2010 (AVADO)</td> <td>58</td> <td>499</td> <td>28</td> <td>231</td> <td>11.8%</td> <td>0.98 [0.63, 1.46]</td> </tr> <tr> <td>Miles D 2017 (MERiDIAN)</td> <td>76</td> <td>239</td> <td>55</td> <td>242</td> <td>14.3%</td> <td>1.40 [1.04, 1.88]</td> </tr> <tr> <td>Miller 2005 (AVF2119g)</td> <td>28</td> <td>229</td> <td>29</td> <td>215</td> <td>10.7%</td> <td>0.91 [0.56, 1.47]</td> </tr> <tr> <td>Miller 2007 (E2100)</td> <td>82</td> <td>365</td> <td>68</td> <td>346</td> <td>14.5%</td> <td>1.14 [0.86, 1.52]</td> </tr> <tr> <td>Minckwitz 2014 (TANIA)</td> <td>45</td> <td>245</td> <td>19</td> <td>238</td> <td>10.3%</td> <td>2.30 [1.39, 3.81]</td> </tr> <tr> <td>Robert 2011 (RIBBON-1 Cape cohort)</td> <td>48</td> <td>404</td> <td>24</td> <td>201</td> <td>11.1%</td> <td>1.00 [0.63, 1.58]</td> </tr> <tr> <td>Robert 2011 (RIBBON-1 T+Antra cohort)</td> <td>79</td> <td>413</td> <td>12</td> <td>202</td> <td>9.1%</td> <td>3.22 [1.80, 5.77]</td> </tr> <tr> <td><b>Total (95% CI)</b></td> <td></td> <td><b>2948</b></td> <td></td> <td><b>1985</b></td> <td><b>100.0%</b></td> <td><b>1.42 [1.10, 1.82]</b></td> </tr> <tr> <td>Total events</td> <td>499</td> <td></td> <td>263</td> <td></td> <td></td> <td></td> </tr> <tr> <td colspan="7">Heterogeneity: Tau<sup>2</sup> = 0.08; Chi<sup>2</sup> = 23.02, df = 8 (P = 0.003); I<sup>2</sup> = 65%</td> </tr> <tr> <td colspan="7">Test for overall effect: Z = 2.73 (P = 0.006)</td> </tr> </tbody> </table>					Study or Subgroup	Beva+CTx Events	Total	CTx Events	Total	Weight	Risk Ratio M-H, Random, 95% CI	Brufsky 2011 (RIBBON-2)	61	458	16	221	10.0%	1.84 [1.09, 3.11]	Martin 2011	22	96	12	89	8.2%	1.70 [0.89, 3.23]	Miles 2010 (AVADO)	58	499	28	231	11.8%	0.98 [0.63, 1.46]	Miles D 2017 (MERiDIAN)	76	239	55	242	14.3%	1.40 [1.04, 1.88]	Miller 2005 (AVF2119g)	28	229	29	215	10.7%	0.91 [0.56, 1.47]	Miller 2007 (E2100)	82	365	68	346	14.5%	1.14 [0.86, 1.52]	Minckwitz 2014 (TANIA)	45	245	19	238	10.3%	2.30 [1.39, 3.81]	Robert 2011 (RIBBON-1 Cape cohort)	48	404	24	201	11.1%	1.00 [0.63, 1.58]	Robert 2011 (RIBBON-1 T+Antra cohort)	79	413	12	202	9.1%	3.22 [1.80, 5.77]	<b>Total (95% CI)</b>		<b>2948</b>		<b>1985</b>	<b>100.0%</b>	<b>1.42 [1.10, 1.82]</b>	Total events	499		263				Heterogeneity: Tau <sup>2</sup> = 0.08; Chi <sup>2</sup> = 23.02, df = 8 (P = 0.003); I <sup>2</sup> = 65%							Test for overall effect: Z = 2.73 (P = 0.006)						
Study or Subgroup	Beva+CTx Events	Total	CTx Events	Total	Weight	Risk Ratio M-H, Random, 95% CI																																																																																																	
Brufsky 2011 (RIBBON-2)	61	458	16	221	10.0%	1.84 [1.09, 3.11]																																																																																																	
Martin 2011	22	96	12	89	8.2%	1.70 [0.89, 3.23]																																																																																																	
Miles 2010 (AVADO)	58	499	28	231	11.8%	0.98 [0.63, 1.46]																																																																																																	
Miles D 2017 (MERiDIAN)	76	239	55	242	14.3%	1.40 [1.04, 1.88]																																																																																																	
Miller 2005 (AVF2119g)	28	229	29	215	10.7%	0.91 [0.56, 1.47]																																																																																																	
Miller 2007 (E2100)	82	365	68	346	14.5%	1.14 [0.86, 1.52]																																																																																																	
Minckwitz 2014 (TANIA)	45	245	19	238	10.3%	2.30 [1.39, 3.81]																																																																																																	
Robert 2011 (RIBBON-1 Cape cohort)	48	404	24	201	11.1%	1.00 [0.63, 1.58]																																																																																																	
Robert 2011 (RIBBON-1 T+Antra cohort)	79	413	12	202	9.1%	3.22 [1.80, 5.77]																																																																																																	
<b>Total (95% CI)</b>		<b>2948</b>		<b>1985</b>	<b>100.0%</b>	<b>1.42 [1.10, 1.82]</b>																																																																																																	
Total events	499		263																																																																																																				
Heterogeneity: Tau <sup>2</sup> = 0.08; Chi <sup>2</sup> = 23.02, df = 8 (P = 0.003); I <sup>2</sup> = 65%																																																																																																							
Test for overall effect: Z = 2.73 (P = 0.006)																																																																																																							
	コメント：Beva群で有意にToxicity(therapy discontinuation)が高い。																																																																																																						
ファンネル プロット																																																																																																							
	コメント：出版バイアスは大きくはない																																																																																																						
その他の解析	施行せず			コメント：																																																																																																			
メタリグ レッション																																																																																																							
感度分析																																																																																																							

【SR-10 メタアナリシス】

CQ		HER2陰性転移・再発乳癌に対する一次・二次治療化学療法として、ベバシズマブを併用することは推奨されるか？																																																																																
P	HER2陰性転移・再発乳癌（女性）	I	ベバシズマブ+化学療法																																																																															
C	化学療法	O	Toxicity (Grade3以上)																																																																															
研究デザイン	RCT	文献数	6																																																																															
コード	Miles2010(AVADO), Robert2011(RIBBON-1), Brufsky2011(RIBBON-2), Minckwitz2014(TANIA), Miles D2017(MERiDian)																																																																																	
モデル	Random Effect	方法	Mantel-Haenszel method																																																																															
効果指標	Risk Ratio	統合値	1.51 (1.30-1.75 ) P< 0.00001																																																																															
フォレスト プロット	<table border="1"> <thead> <tr> <th>Study or Subgroup</th> <th>Beva+CTx Events</th> <th>Total</th> <th>CTx Events</th> <th>Total</th> <th>Weight</th> <th>Risk Ratio M-H, Random, 95% CI</th> </tr> </thead> <tbody> <tr> <td>Brufsky 2011 (RIBBON-2)</td> <td>161</td> <td>458</td> <td>50</td> <td>221</td> <td>14.2%</td> <td>1.55 [1.18, 2.04]</td> </tr> <tr> <td>Miles 2010 (AVADO)</td> <td>187</td> <td>498</td> <td>72</td> <td>231</td> <td>17.0%</td> <td>1.20 [0.96, 1.50]</td> </tr> <tr> <td>Miles D 2017 (MERIDIAN)</td> <td>179</td> <td>238</td> <td>96</td> <td>233</td> <td>20.3%</td> <td>1.83 [1.54, 2.16]</td> </tr> <tr> <td>Minckwitz 2014 (TANIA)</td> <td>145</td> <td>245</td> <td>109</td> <td>238</td> <td>20.1%</td> <td>1.28 [1.09, 1.54]</td> </tr> <tr> <td>Robert 2011 (RIBBON-1 Cape cohort)</td> <td>143</td> <td>404</td> <td>44</td> <td>201</td> <td>13.2%</td> <td>1.62 [1.21, 2.17]</td> </tr> <tr> <td>Robert 2011 (RIBBON-1 T+Antra cohort)</td> <td>188</td> <td>413</td> <td>54</td> <td>202</td> <td>15.3%</td> <td>1.70 [1.32, 2.19]</td> </tr> <tr> <td><b>Total (95% CI)</b></td> <td></td> <td><b>2257</b></td> <td></td> <td><b>1326</b></td> <td><b>100.0%</b></td> <td><b>1.51 [1.30, 1.75]</b></td> </tr> <tr> <td>Total events</td> <td>1003</td> <td></td> <td>425</td> <td></td> <td></td> <td></td> </tr> <tr> <td colspan="7">Heterogeneity: Tau<sup>2</sup> = 0.02; Chi<sup>2</sup> = 13.06, df = 5 (P = 0.02); I<sup>2</sup> = 62%</td> </tr> <tr> <td colspan="7">Test for overall effect: Z = 5.50 (P &lt; 0.00001)</td> </tr> </tbody> </table> <p>コメント：Beva群で有意にToxicity(グレード3以上)が高い。</p>					Study or Subgroup	Beva+CTx Events	Total	CTx Events	Total	Weight	Risk Ratio M-H, Random, 95% CI	Brufsky 2011 (RIBBON-2)	161	458	50	221	14.2%	1.55 [1.18, 2.04]	Miles 2010 (AVADO)	187	498	72	231	17.0%	1.20 [0.96, 1.50]	Miles D 2017 (MERIDIAN)	179	238	96	233	20.3%	1.83 [1.54, 2.16]	Minckwitz 2014 (TANIA)	145	245	109	238	20.1%	1.28 [1.09, 1.54]	Robert 2011 (RIBBON-1 Cape cohort)	143	404	44	201	13.2%	1.62 [1.21, 2.17]	Robert 2011 (RIBBON-1 T+Antra cohort)	188	413	54	202	15.3%	1.70 [1.32, 2.19]	<b>Total (95% CI)</b>		<b>2257</b>		<b>1326</b>	<b>100.0%</b>	<b>1.51 [1.30, 1.75]</b>	Total events	1003		425				Heterogeneity: Tau <sup>2</sup> = 0.02; Chi <sup>2</sup> = 13.06, df = 5 (P = 0.02); I <sup>2</sup> = 62%							Test for overall effect: Z = 5.50 (P < 0.00001)						
Study or Subgroup	Beva+CTx Events	Total	CTx Events	Total	Weight	Risk Ratio M-H, Random, 95% CI																																																																												
Brufsky 2011 (RIBBON-2)	161	458	50	221	14.2%	1.55 [1.18, 2.04]																																																																												
Miles 2010 (AVADO)	187	498	72	231	17.0%	1.20 [0.96, 1.50]																																																																												
Miles D 2017 (MERIDIAN)	179	238	96	233	20.3%	1.83 [1.54, 2.16]																																																																												
Minckwitz 2014 (TANIA)	145	245	109	238	20.1%	1.28 [1.09, 1.54]																																																																												
Robert 2011 (RIBBON-1 Cape cohort)	143	404	44	201	13.2%	1.62 [1.21, 2.17]																																																																												
Robert 2011 (RIBBON-1 T+Antra cohort)	188	413	54	202	15.3%	1.70 [1.32, 2.19]																																																																												
<b>Total (95% CI)</b>		<b>2257</b>		<b>1326</b>	<b>100.0%</b>	<b>1.51 [1.30, 1.75]</b>																																																																												
Total events	1003		425																																																																															
Heterogeneity: Tau <sup>2</sup> = 0.02; Chi <sup>2</sup> = 13.06, df = 5 (P = 0.02); I <sup>2</sup> = 62%																																																																																		
Test for overall effect: Z = 5.50 (P < 0.00001)																																																																																		
ファンネル プロット	<p>コメント：出版バイアスは大きくはない</p>																																																																																	
その他の解析	施行せず			コメント：																																																																														
メタリグ レッション																																																																																		
感度分析																																																																																		